The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

"This is a historic moment for 4DMT as we become a Phase 3 company following our initiation of the 4FRONT-1 clinical trial,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.

Roche’s RHHBY member company, Genentech, announced the FDA approval of TNKase (tenecteplase), a thrombolytic or ...

The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according ...

Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment ...

Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populatio ...

As a result, cash runway extended into 2028 and includes full execution and topline 52-week data from 4FRONT-1 and 4FRONT-2 Phase 3 clinical trials in wet AMD, and ongoing Phase 1 & 2 clinical ...

plus freedom from frequent bolus injections. 4D-150’s target product profile is designed to allow for seamless adoption into retina clinic practices and for pricing flexibility augmented by our ...

If you're thinking of getting an injection for back pain, you might want to think again. A panel of experts has examined the practice, found serious issues with its use – including financial ...

A trigger point injection is a superficial (shallow) pain-relief injection into muscles under tension in any part of the body that have an electrical connection to other parts of that muscle or muscle ...

The clinic claimed the injections were steroids that would relieve her pain, Shaw said, but with each shot her agony would grow. Shaw said she eventually tried to decline the shots, then the clinic ...

Epidural steroid injections (ESIs) offer limited effectiveness in reducing back pain and disability, an updated review by the American Academy of Neurology (AAN) suggested. “They may modestly ...